SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
DENDREON CORP
(NQNM:DNDN Last Sale: 3.1 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (DNDN : $3.1)
$313 million Market Cap at September 12, 2013
Employs 200.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
3005 First Avenue Research Report Earnings Snapshot - Last 08/11/18
Seattle, WA 98121 Fact Sheet
Phone: (206) 256-4545 Financial Statements
Peer Comparison
Annual Reports

William Crouse, Chmn., Mitchell H. Gold, Pres./CEO, Gregory T. Schiffman, CFO
Bankrutcy filing November 10, 2014. Disappointment with Provenge prostate cancer vaccine August 4, 2011. Trading halt April 28, 2009 after results on trial of prostate cancer therapy treatment - Provenge. IPO at $10 June 15, 2000. Raised $45 million, selling 4.5 million shares, 22% of the outstanding. Lead Manager: Prudential. Acquired CORVAS INTERNATIONAL INC (Nasdaq:CVAS) July 30, 2003 for 12.4 million shares, issuing 0.45 DNDN per CVAS. FDA approved prostrate cancer drug PROVENGE March 29, 2007.
Historical Charts    Technical Analysis
No Historical Data available for DNDN

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common DNDN $3.1 $ 0 $2.97 $3.13 2,903,836 $2.69 $7.22 100,852
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $312,641

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex